Immunotherapy in Melanoma | Specialty

COMBI-AD: Implications for Melanoma Patients

September 22nd 2017

A New Standard for Stage 3 BRAF+ Melanoma

September 22nd 2017

Avelumab Approved in Europe for Merkel Cell Carcinoma

September 21st 2017

The European Commission has approved avelumab (Bavencio) for the treatment of patients with metastatic Merkel cell carcinoma.

Neutrophil to Lymphocyte Ratio Predicts Survival in Metastatic Melanoma

September 20th 2017

The neutrophil-to-lymphocyte ratio is an independent factor for overall survival in patients with metastatic melanoma, whether they receive targeted therapy or immunotherapy.

FDA Accepts Filing for Binimetinib/Encorafenib Combo in BRAF+ Melanoma

September 14th 2017

The FDA has accepted new drug applications supporting use of the combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib for BRAF-mutant advanced, unresectable or metastatic melanoma.

Neoadjuvant Dabrafenib/Trametinib Leads to High pCR Rates in Bulky Resectable Melanoma, But Recurrences Are Common

September 13th 2017

Nearly half of patients with resectable stage IIIB/C BRAF V600-mutant melanoma achieved pathologic complete response with neoadjuvant combination therapy consisting of dabrafenib (Tafinlar) and trametinib (Mekinist).

Disease-Free Survival Gains Reported for Vemurafenib in Stage IIC-IIIB Melanoma

September 13th 2017

Adjuvant therapy with vemurafenib for high-risk melanoma led to mixed results, as patients with stage IIIC or later did not benefit, but those with earlier stage disease did.

Dr. Dummer on COMBI-AD Trial Results in BRAF-Mutant Melanoma

September 13th 2017

Reinhard Dummer, MD, of University Hospital Zurich, discusses the results of the phase III COMBI-AD study presented at the 2017 ESMO Congress in patients with stage III BRAF-mutant melanoma.

Nivolumab Superior to Ipilimumab as Adjuvant Therapy for Stage III/IV Resected Melanoma

September 12th 2017

Nivolumab (Opdivo) may represent a new standard option for adjuvant therapy for patients with resected stage IIIB/C and IV melanoma, whether or not they have a BRAF mutation. In a comparison with current standard high-dose ipilimumab (Yervoy), nivolumab demonstrated a significant improvement in relapse-free survival.

Dr. Hamid on Epacadostat Plus Pembrolizumab in Advanced Melanoma

September 11th 2017

Omid Hamid, MD, director of the melanoma center at the Angeles Clinic & Research Institute in Los Angeles, discusses the phase III results of the ECHO-202/KEYNOTE-037 trial, which explored the IDO inhibitor epacadostat plus pembrolizumab (Keytruda) in patients with advanced melanoma.

Dr. Weber on CheckMate-238 for Melanoma

September 11th 2017

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the CheckMate-238 trial for patients with melanoma.

Adjuvant Dabrafenib/Trametinib Doubles RFS for BRAF+ Melanoma

September 11th 2017

Adjuvant treatment with dabrafenib and trametinib reduced the risk of relapse or death by 53% compared with placebo for patients with stage III BRAF-mutant melanoma.

PD-1/IDO Combination Active in Advanced Melanoma

September 10th 2017

A majority of patients with advanced melanoma responded to the combination of pembrolizumab and the investigational IDO1 inhibitor epacadostat.

Binimetinib Adds to Encorafenib PFS Benefit for BRAF+ Melanoma

September 9th 2017

The combination of encorafenib and binimetinib demonstrated significant improvements in PFS compared with single-agent vemurafenib or encorafenib for patients with BRAF-mutant advanced melanoma.

FDA Grants Cemiplimab Breakthrough Designation for CSCC

September 9th 2017

The FDA has granted a breakthrough therapy designation to cemiplimab (REGN2810) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) and adults with locally advanced and unresectable CSCC.

Dr. Gandara Discusses PD-L1 as a Biomarker in Lung Cancer

September 8th 2017

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer, discusses PD-L1 as a biomarker in lung cancer.

Dr. Ross Discusses the Future Treatment Landscape of Melanoma

September 8th 2017

Merrick I. Ross, MD, professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the future treatment landscape of melanoma.

Update Confirms Benefit of Pembrolizumab Plus Indoximod in Melanoma

September 7th 2017

Adding the IDO inhibitor indoximod to pembrolizumab (Keytruda) led to an overall response rate of 61% in patients with advanced melanoma.

FDA Grants LN-144 Fast Track Status for Melanoma

September 1st 2017

The FDA has granted LN-144, an adoptive cell therapy that uses tumor-infiltrating lymphocyte technology developed by Iovance Biotherapeutics, a fast track designation for the treatment of patients with advanced melanoma.

Dr. Daud Discusses the Current Status of Immunotherapy in Melanoma

August 28th 2017

Adil Daud, MD, clinical professor, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, at University of California, San Francisco, discusses the current status of immunotherapy in melanoma.